Gilead’s Kite agrees $350m deal to acquire US biotech Interius BioTherapeutics
Will expand the company’s CAR T-cell therapy footprint and gain access next generation in vivo technology.
List view / Grid view
Will expand the company’s CAR T-cell therapy footprint and gain access next generation in vivo technology.
Her leadership experience spans three decades with Lilly, across multiple therapeutic areas including oncology, neuroscience and infectious disease.
The paper explores recent guidance by the EMA and aims to help companies ensure their developments are efficient and effective for the forthcoming transition.
The German pharma company’s BioXcellence arm will supply the drug substance for AnGes’ peripheral arterial disease treatment Collategene.
The drug is the first treatment for desmoid tumours to be approved in the region.
Disruption to traditional distribution channels is anticipated to hinder widespread adoption of the channel.
The Australian biotech's new operating model will also see medical and commercial functions at its CSL Behring and CSL Vifor units combined.
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
Further to its potential in Stargardt disease, if approved, the one-time gene therapy could become standard of care for retinitis pigmentosa, alongside other retinal degenerative diseases.
Becomes the first monoclonal antibody for the condition to be approved by the MHRA and advances the pharma company’s ambitions in diabetes.
Draft publication is set to expand its frameworks for new medicinal products, including cell and gene therapies.
Pharmacokinetic study of the novel drug delivery method shows high relative bioavailability in a once-weekly regimen.
Calls for active pharmaceutical ingredient (API) stockpile to cover around 26 ‘critical drugs’.
The pharma company will add to its existing Chicago site, boosting its active pharmaceutical ingredient production capacity.
Sven Dethlefs will be tasked with driving its deupirfenidone programme in idiopathic pulmonary fibrosis.